NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

Michelle Krogsgaard, PhD, associate professor, Department of Pathology, NYU Langone's Perlmutter Cancer Center, discusses mechanisms of resistance to PD-1 checkpoint blockade.

Jeffrey S. Weber, MD, PhD, discusses the promise of nivolumab in this setting and a general overview of the melanoma treatment landscape.

Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone’s Perlmutter Cancer Center, discusses whether the number of prior lines of therapy impact response to immunotherapy in patients with triple-negative breast cancer (TNBC).

Ophira Ginsburg, MD, discusses cervical cancer prevention, screening, and elimination on a global scale.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses a study of an immunotherapy combination in bladder cancer.

Yelena Novik, MD, associate professor, New York University’s Perlmutter Cancer Center, discusses the benefits and challenges of the global implementation of biosimilars.

Naamit K. Gerber, MD, discusses recent advances in radiation therapy in the field of breast cancer.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses updated data for the Checkmate-238 trial.

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses global vaccination and screening for cervical cancer.

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses cervical cancer disparities in low-income countries.

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of the combination of durvalumab (Imfinzi) plus tremelimumab in metastatic bladder cancer.

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the importance of mutational analysis in the treatment of patients with pancreatic cancer.

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the role of radiotherapy in oligometastatic non–small cell lung cancer (NSCLC).

Jeffrey S. Weber, MD, PhD, the Laura and Isaac Perlmutter Professor of Oncology, co-director of the Melanoma Research Program, deputy director of the Perlmutter Cancer Center, NYU Langone Medical Center, and a 2016 Giant of Cancer Care® in Melanoma, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses unmet needs in the treatment of patients with pancreatic cancer.

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, addresses global disparities in cervical cancer.

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care® in Melanoma, discusses the side effect profile of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with melanoma.

William C. Huang, MD, associate professor, department of Urology, co-director, Robotics Program, Chief Urology Service, Tisch Hospital, NYU Langone Health, discusses misconceptions regarding robotic-assisted bladder surgery.

Selective bladder preservation has been suggested as a potential alternative to cystectomy in patients with bladder cancer who have a transitional cell carcinoma pathology.

Jeffrey S. Weber, MD, PhD, discusses the future of immunotherapy in the treatment of melanoma.

Jeffrey S. Weber, MD, PhD, Laura and Isaac Perlmutter Professor of Oncology, deputy director, co-director of the Melanoma Research Program, NYU Langone’s Perlmutter Cancer Center, discusses the clinical potential and monetary hindrances of triplet and four-drug regimens for patients with melanoma.

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone's Perlmutter Cancer Center, discusses the sequencing of agents for patients with ovarian cancer.

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.

Douglas Levine, MD, provides his insight on some of the recent data with PARP inhibitors in ovarian cancer, as well as his predictions for the field in the next several years.

Checkpoint inhibitors against PD-1 and PD-L1 have shown promise, both as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer.

Findings from a clinical trial led by a researcher at NYU Langone's Perlmutter Cancer Center helped pave the way for the recent, accelerated approval by the US Food and Drug Administration of a highly effective immunotherapy as first-line treatment for patients with advanced bladder cancer who are not eligible for treatment with standard chemotherapy.

Arjun V. Balar, MD, discusses the impact of the approval of pembrolizumab and other immunotherapy agents in urothelial carcinoma, as well as the next steps with these treatments.

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses sequencing challenges as well as emerging agents in the field of ALK-positive non–small cell lung cancer (NSCLC).